Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
This open-label trial is composed of two periods: Induction and Extension. All eligible patients will be enrolled into the 12-Week Induction period and receive study medication. Patients who complete the Induction period may then be eligible to enter the 100-Week Extension period where they will continue to receive study medication.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Crohn's disease (CD) confirmed by endoscopy and histology
Active disease as evaluated by Crohn's Disease Activity Index Score and Simple Endoscopic Score for CD
Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic therapy
You may not be if
Diagnosis of ulcerative colitis or indeterminate colitis
Known strictures/stenosis leading to symptoms of obstruction
Current stoma or need for ileostomy or colostomy
Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk
